AUS
NZ
UK
CA
USA
IND
Highlights
- HERACLES trial progresses with next dosing stage approved
- Sofra platform demonstrates adaptability in immune and cancer research
- Collaboration advances towards animal model studies
Noxopharm (ASX:NOX) has taken another step forward in its HERACLES trial for SOF-SKN, a novel therapy designed to address autoimmune conditions such as cutaneous lupus erythematosus (CLE). The trial, conducted in Australia, follows a careful, staged approach to dose escalation. Each group of participants is closely monitored, and only after safety clearance from an independent committee does the trial move to the next stage.
This structured process aims to identify the most suitable dosage for further development while ensuring patient safety remains a top priority. The Australian trial setting also supports access to specialist expertise and government research incentives.
Expanding Treatment Horizons with Sofra Technology
SOF-SKN is built on Noxopharm’s Sofra platform, which uses proprietary oligonucleotide technology to regulate inflammation directly at its source. While CLE is the initial target, the treatment approach holds scope for a wide range of autoimmune and inflammatory disorders, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease.
The Sofra platform’s versatility has attracted international research partnerships. In the United States, a collaboration has produced encouraging preclinical results that could expand its use into cancer and other inflammation-driven diseases. While Noxopharm is not currently part of the ASX 200, the company’s developments are closely watched by industry observers due to their potential impact on multiple therapeutic markets.
US Collaboration Adds New Dimension
A partnership with Tezcat Biosciences in New York has shown that Sofra’s oligonucleotides can be successfully paired with targeted drug delivery systems aimed at immune and cancer cells. Laboratory studies revealed strong anti-inflammatory activity, demonstrating the platform’s flexibility across different administration methods.
This complements Noxopharm’s existing research, which includes topical applications in HERACLES and other advanced delivery approaches. The next step in the collaboration will see the program move into animal model studies to further explore systemic delivery opportunities.
Frequently Asked Questions
- What is the goal of the HERACLES trial?
The HERACLES trial is designed to evaluate the safety and effectiveness of SOF-SKN in treating autoimmune conditions such as CLE. - How does the Sofra platform work?
The Sofra platform uses specialised oligonucleotides to target and regulate inflammation at its root cause, potentially benefiting a wide range of conditions. - What’s next for the US collaboration?
The partnership plans to progress into animal studies to assess the systemic delivery of Sofra-based therapies for broader disease applications.
